ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2021

Abstract Number: 0359

Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)

Marco Garrido-Cumbrera1, Denis Poddubnyy2, Christine Bundy3, Laura Christen4, Raj Mahapatra5, Souzi Makri6, Carlos Jesús Delgado-Domínguez7, Sergio Sanz-Gomez7, Pedro Plazuelo-Ramos8 and Victoria Navarro-Compán9, 1Health & Territory Research (HTR), University of Seville, Sevilla, Spain, 2Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, 3Cardiff University, Cardiff, Wales, United Kingdom, 4Novartis Pharma AG, Basel, Switzerland, 5Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, 6Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, 7Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, 8Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, 9Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2021

Keywords: Ankylosing spondylitis (AS), Disease Activity, Health Care, Patient reported outcomes, spondyloarthritis

Session Information

Date: Saturday, November 6, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The journey of axial spondyloarthritis (axSpA) for most patients is slow and arduous. The goal of this analysis is to assess the journey to diagnosis and further management in axSpA patients.

Methods: Data from 2,846 unselected patients from EMAS, generated through an online survey (2017-2018) across 13 European countries were analysed. Descriptive analysis of sociodemographic factors, insurance scheme, diagnostic journey and post diagnosis healthcare utilization was performed. The Mann-Whitey test was used to analyse possible differences between BASDAI and the number of visits to healthcare professionals and followup tests undertaken.

Results: The mean age was 43.9 years, 61.3% were female, 48.1% university educated, 67.9% married, 53.9% employed and 81.7% had public health insurance. Mean age at symptoms onset was 26.6 (11.1), while mean age at diagnosis was 33.7 (11.5) and mean diagnostic delay was 7.4 years. Over 50% had a diagnostic delay of >4 years. Prior to receiving a diagnosis, patients visited on average 2.6 specialists. The most commonly performed diagnostic tests were x-rays (72.3%), HLA B27 tests (65.4%) and MRIs (64.3%). 78.4% were diagnosed by a rheumatologist while 14.9% received their diagnosis by a General Practitioner (GP). Patients who experienced a diagnostic delay of more than a year (n=2,208) undertook a considerable number of visits to specialists and medical tests in the year prior to participating in EMAS, which increased with disease activity. Patients with active disease (BASDAI >4) reported a higher number of visits to rheumatologists (3.7±3.5 vs 2.9±2.6), general practitioners (6.6±10.0 vs 3.5±4.1), physiotherapists (19.3±25.0 vs 11.7±17.0), and psychologists/psychiatrists (3.4±10.7 vs 1.9±7.7). Regarding follow-up tests, they also undertook more x-rays (1.8 ± 2.8 vs. 1.3 ± 1.9), MRI scans (0.9 ± 1.2 vs. 0.6 ± 1.1), and blood tests (4.7 ± 4.4 vs 3.6 ± 3.2) compared to patients with inactive disease (Figure 1). However, one in five patients visited the rheumatologist only once in the year prior to EMAS (21.1%).

Conclusion: Diagnostic delay continues to be a key challenge in the axSpA patient journey, with patients waiting an average of 7.4 years and visiting multiple doctors and undertaking a significant number of medical tests prior to diagnosis. Once diagnosed, disease management presents a further challenge, as patients with higher disease activity reported more healthcare professional visits as well as medical tests. Safeguarding health and controlling healthcare utilization requires effective disease management, greater education for non-specialists, rapid referral routes for diagnosis and collaborative care between specialists and nonspecialists.

Figure 1. Diagnostic pathway of EMAS axSpA patients


Disclosures: M. Garrido-Cumbrera, None; D. Poddubnyy, AbbVie, 2, 5, 6, Eli Lilly and Company, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 6, BMS, 2, 6, Roche, 2, 6; C. Bundy, Abbvie, 2, Celgene, 2, Janssen, 2, Lilly, 2, Novartis, 2, Pfizer, 2; L. Christen, Novartis, 3; R. Mahapatra, None; S. Makri, None; C. Delgado-Domínguez, None; S. Sanz-Gomez, None; P. Plazuelo-Ramos, None; V. Navarro-Compán, Abbvie, 5, Lilly, 5, Novartis, 5, Pfizer, 5, UCB, 5, Janssen, 5.

To cite this abstract in AMA style:

Garrido-Cumbrera M, Poddubnyy D, Bundy C, Christen L, Mahapatra R, Makri S, Delgado-Domínguez C, Sanz-Gomez S, Plazuelo-Ramos P, Navarro-Compán V. Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/patient-journey-with-axial-spondyloarthritis-critical-issues-from-the-patient-perspective-results-from-the-european-map-of-axial-spondyloarthritis-emas/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-journey-with-axial-spondyloarthritis-critical-issues-from-the-patient-perspective-results-from-the-european-map-of-axial-spondyloarthritis-emas/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology